NovoCure Limited is a global oncology company with a proprietary platform technology called Tumor Treating Fields (TTFields), which are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. The Company's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Its Optune Gio is approved by the FDA under the Premarket Approval pathway for the treatment of adult patients with newly diagnosed glioblastoma together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Its Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic non-small cell lung cancer concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļNVCR
āļāļ·āđāļāļāļĢāļīāļĐāļąāļNovocure Ltd
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļOct 01, 2015
āļāļĩāļāļĩāđāļLeonard (Francis X)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ1488
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļOct 01
āļāļĩāđāļāļĒāļđāđNo. 4 The Forum
āđāļĄāļ·āļāļSAINT HELIER
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻJersey
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđJE2 4UF
āđāļāļĢāļĻāļąāļāļāđ441534756700
āđāļ§āđāļāđāļāļāđhttps://www.novocure.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļNVCR
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļOct 01, 2015
āļāļĩāļāļĩāđāļLeonard (Francis X)
Mr. William F. (Bill) Doyle
Mr. William F. (Bill) Doyle
Executive Chairman of the Board
Executive Chairman of the Board
Mr. William F. (Bill) Doyle
Mr. William F. (Bill) Doyle
Executive Chairman of the Board
Executive Chairman of the Board
Mr. William F. (Bill) Doyle
Mr. William F. (Bill) Doyle
Executive Chairman of the Board
Executive Chairman of the Board
Mr. Asaf Danziger
Director
Mr. Asaf Danziger
Director
Mr. Asaf Danziger
Director
Dr. Uri Weinberg, M.D., Ph.D.
Dr. Uri Weinberg, M.D., Ph.D.
Chief Medical Officer, Chief Innovation Officer
Chief Medical Officer, Chief Innovation Officer
Dr. Uri Weinberg, M.D., Ph.D.
Dr. Uri Weinberg, M.D., Ph.D.
Chief Medical Officer, Chief Innovation Officer
Chief Medical Officer, Chief Innovation Officer
Dr. Uri Weinberg, M.D., Ph.D.
Dr. Uri Weinberg, M.D., Ph.D.
Chief Medical Officer, Chief Innovation Officer
Chief Medical Officer, Chief Innovation Officer
Mr. Christoph Brackmann
Chief Financial Officer
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Mr. William F. (Bill) Doyle
Mr. William F. (Bill) Doyle
Executive Chairman of the Board
Executive Chairman of the Board
Mr. William F. (Bill) Doyle
Mr. William F. (Bill) Doyle
Executive Chairman of the Board
Executive Chairman of the Board
Mr. William F. (Bill) Doyle
Mr. William F. (Bill) Doyle
Executive Chairman of the Board
Executive Chairman of the Board
Mr. Asaf Danziger
Director
Mr. Asaf Danziger
Director
Mr. Asaf Danziger
Director